Rodman & Renshaw initiated coverage on Talphera with a new price target
$TLPH
Biotechnology: Pharmaceutical Preparations
Health Care
Rodman & Renshaw initiated coverage of Talphera with a rating of Buy and set a new price target of $4.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/28/2025 | $4.00 | Buy | Rodman & Renshaw |
SAN MATEO, Calif., Nov. 5, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release third quarter 2025 financial results after market close on Wednesday, November 12, 2025, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss the results and provide an update on the Company's business. Webcast Information The webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the webcast lin
SAN MATEO, Calif., Oct. 21, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the appointment of Joe Todisco, the CEO of CorMedix Inc. (NASDAQ:CRMD) to its Board of Directors. In September 2025, CorMedix made a strategic investment in Talphera as part of the company's private placement financing. In connection with the closing of this transaction, CorMedix has the right to nominate a representative to the Talphera Board of Directors. The Company also provided CorMedix with a 60-day exclusive negotiation period follo
CorMedix is making a strategic investment in Talphera as the lead investor, supported by existing stockholders Nantahala, Rosalind and Rock Springs with several new institutional investors $17 million in proceeds at first closing with the potential to receive an additional $12 million across one additional tranche upon the achievement of the primary endpoint in the NEPHRO clinical study The completion of this financing is expected to provide the company with sufficient capital through the planned approval of a Niyad PMA in the second half of 2026 SAN MATEO, Calif., Sept. 8, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), (Talphera), a specialty pharmaceutical company focused on the develo
S-3 - TALPHERA, INC. (0001427925) (Filer)
S-8 - TALPHERA, INC. (0001427925) (Filer)
8-K - TALPHERA, INC. (0001427925) (Filer)
Rodman & Renshaw initiated coverage of Talphera with a rating of Buy and set a new price target of $4.00
4 - TALPHERA, INC. (0001427925) (Issuer)
4 - TALPHERA, INC. (0001427925) (Issuer)
4 - TALPHERA, INC. (0001427925) (Issuer)
4 - TALPHERA, INC. (0001427925) (Issuer)
4 - TALPHERA, INC. (0001427925) (Issuer)
4 - TALPHERA, INC. (0001427925) (Issuer)
SAN MATEO, Calif., Oct. 21, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the appointment of Joe Todisco, the CEO of CorMedix Inc. (NASDAQ:CRMD) to its Board of Directors. In September 2025, CorMedix made a strategic investment in Talphera as part of the company's private placement financing. In connection with the closing of this transaction, CorMedix has the right to nominate a representative to the Talphera Board of Directors. The Company also provided CorMedix with a 60-day exclusive negotiation period follo
ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. "I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive
SAN MATEO, Calif., Nov. 5, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release third quarter 2025 financial results after market close on Wednesday, November 12, 2025, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss the results and provide an update on the Company's business. Webcast Information The webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the webcast lin
New sites accelerate registrational study enrollment - 15 patients have been enrolled in the NEPHRO study which remains on track with completion projected by the end of the year Cash and cash equivalents at June 30, 2025 were $6.8 million Conference call and webcast to be held Thursday, August 14, 2025 at 4:30 pm ET SAN MATEO, Calif., Aug. 14, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced second quarter 2025 financial results and provided a corporate update. "We have enrolled 15 patients in the NEPHRO clinical
SAN MATEO, Calif., Aug. 7, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release second quarter 2025 financial results after market close on Thursday, August 14, 2025, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss the results and provide an update on the Company's business. Webcast Information The webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the webcast link